Health Condition 1: M849- Disorder of continuity of bone, unspecified
Conditions
Interventions
Intervention1: Magnesium Sulfate 125 mg: Magnesium sulfate, as an adjunct, has been shown to enhance postoperative analgesia. Magnesium is an N-Methyl-D-Aaspartate (NMDA) antagonist and moderates the
Sponsors
Kempegowda Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients aged between 18 years to 60 years 2. Patients with ASA physical status 1 and 2. 3. Scheduled for clavicular and proximal shaft humerus fracture surgeries.
Exclusion criteria
Exclusion criteria: 1. Patients other than ASA physical status 1 and 2. 2.Patients on antiplatelet or anticoagulant drugs. 3.Pregnancy and Lactation. 4. Patients having a. Local infection at the site of block. b. Bleeding coagulopathy. c. Neurological ailments such as peripheral neuropathy, chronic neuropathic pain, nerve injury d. Allergy to local anesthetics and magnesium
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative analgesiaTimepoint: 4, 8, 12 and 24 hours post surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effects of magnesium sulfateTimepoint: 4, 8, 12 and 24 hours post surgery;Motor and sensory blockadeTimepoint: Every ten minutes after surgery till the complete recovery of sensory and motor blockade | — |
Countries
India
Contacts
Public ContactPriyanka Suresh
KIMS, Banaglore
Outcome results
None listed